Drug intelligence / Profile preview

botulinum toxin type F

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intramuscular, Intradermal, Subcutaneous
01

Overview

Botulinum toxin type F is one of the seven antigenically distinct serotypes (A–G) of botulinum neurotoxins produced by the bacterium *Clostridium botulinum* and related species. Like other serotypes, it acts as a potent neurotoxin that blocks neuromuscular transmission by inhibiting acetylcholine release at the neuromuscular junction. Botulinum toxins achieve this effect by binding irreversibly to presynaptic cholinergic nerve terminals and cleaving specific proteins in the SNARE complex required for vesicle fusion and neurotransmitter release. Specifically, type F cleaves synaptobrevin (also known as VAMP), a key component of the SNARE complex[6][8]. This results in flaccid paralysis of affected muscles. While types A and B are most commonly used clinically, type F has been investigated for therapeutic applications such as spastic disorders and dystonias[1][8]. Type A is considered most potent, followed by types B and then F[8].

Other names
BoNT/Fbotulinum neurotoxin type FClostridium botulinum neurotoxin serotype F
02

Targets

VAMP (SNARE Protein Complex)

Beyond the preview

Go deeper on botulinum toxin type F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on botulinum toxin type F.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call